Clearside Announces Pricing of Public Offering of Common Stock

Clearside Biomedical (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the pricing of its underwritten public offering of 6,538,462 shares of its common stock at a price to the public of $13.00 per share.

As quoted in the press release:

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.  Stifel, Nicolaus & Company, Incorporated is acting as a passive book-running manager and Needham & Company, LLC and Wedbush Securities Inc. are acting as co-managers for the offering.  Clearside has granted to the underwriters a 30-day option to purchase up to 980,769 additional shares of common stock at the public offering price, less the underwriting discount.

Click here to read the full press release.